1 – 4 of 4
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2016
-
Mark
Preclinical Characterization of 3β-(N-Acetyl l -cysteine methyl ester)-2aβ,3-dihydrogaliellalactone (GPA512), a Prodrug of a Direct STAT3 Inhibitor for the Treatment of Prostate Cancer
(
- Contribution to journal › Article
-
Mark
N-Conjugate prodrugs of galiellalactone
(
- Contribution to journal › Article
- 2014
-
Mark
Galiellalactone is a Direct Inhibitor of STAT3 in Prostate Cancer Cells.
(
- Contribution to journal › Article
- 2008
-
Mark
Galiellalactone is a novel therapeutic candidate against hormone-refractory prostate cancer expressing activated Stat3.
(
- Contribution to journal › Article